Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: a prospective pilot tri
- PDF / 992,371 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 22 Downloads / 217 Views
Diabetology & Metabolic Syndrome Open Access
RESEARCH
Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: a prospective pilot trial Tao Yuan1†, Shixuan Liu1†, Yingyue Dong1, Yong Fu1, Yan Tang2 and Weigang Zhao1*
Abstract Background: We aimed to evaluate the effects of short-term therapy with dapagliflozin on serum uric acid (SUA) and urinary uric acid (UUA) levels in patients with type 2 diabetes. Methods: In this prospective pilot trial, 8 patients with type 2 diabetes mellitus were assigned to the treatment group with dapagliflozin 10 mg once daily for one week, and 7 subjects with normal glucose tolerance were recruited into the control group. Data of anthropometric measurements, SUA, 24-h UUA, fractional excretion of UA (FEUA), serum lipid parameters and 3-h oral glucose tolerance test (OGTT) were collected in both treatment and control groups; all examinations were repeated after treatment. The area under the curve of glucose (AUCGlu) was calculated to reflect the general glucose levels, while insulin resistance and islet β-cell function were reflected by indexes calculated according to the data obtained from the OGTT. Results: The weight and serum lipid parameters showed no differences before and after treatment with dapagliflozin for one week. We found SUA levels decreased from 347.75 ± 7.75 μmol/L before treatment to 273.25 ± 43.18 μmol/L after treatment, with a statistically significant difference (P = 0.001) and was accompanied by a significant increase in FEUA from 0.009 to 0.029 (P = 0.035); there was a linear correlation between SUA and FEUA levels. Glucose control, insulin sensitivity and islet β-cell function were improved to a certain extent. We also found a positive correlation between the decrease in glucose levels and the improvement in islet β-cell function. Conclusions: The SUA-lowering effect of dapagliflozin could be driven by increasing UA excretion within one week of treatment, and a certain degree of improvement in glucose levels and islet β-cell function were observed. Trial registration ClinicalTrials.gov identifier, NCT04014192. Registered 12 July 2019, https://www.clinicaltrials.gov/ct2/ show/NCT04014192:term=NCT04014192&draw=2&rank=1. Yes. Keywords: Serum uric acid, Fractional excretion of uric acid, Dapagliflozin, Type 2 diabetes mellitus, Islet β-cell function, SGLT2 inhibitors
*Correspondence: [email protected] † Tao Yuan and Shixuan Liu contributed equally to this work 1 Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Shuaifuyuan Street No.1, Dongcheng District, Beijing 100730, China Full list of author information is available at the end of the article
Background Type 2 diabetes mellitus (T2DM) is a complex metabolic disease, which is characterized by insulin resistance of different insulin target tissues (including liver, adipose tissue, and skeletal muscle) a
Data Loading...
